David D. Chang - May 24, 2021 Form 4 Insider Report for Allogene Therapeutics, Inc. (ALLO)

Role
President and CEO, Director
Signature
/s/ Veer Bhavnagri, Attorney-in-Fact
Stock symbol
ALLO
Transactions as of
May 24, 2021
Transactions value $
$499,410
Form type
4
Date filed
5/26/2021, 08:00 AM
Next filing
Mar 17, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALLO Common Stock Options Exercise $499K +27.4K +1.2% $18.22 2.31M May 24, 2021 Direct
holding ALLO Common Stock 1.2M May 24, 2021 See footnote F1
holding ALLO Common Stock 856K May 24, 2021 See footnote F2
holding ALLO Common Stock 856K May 24, 2021 See footnote F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALLO Stock Option (Right to Buy) Options Exercise $0 -27.4K -4.82% $0.00 541K May 24, 2021 Common Stock 27.4K $18.22 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Securities held in the name of the Chang 2006 Family Trust.
F2 Securities held in the name of the JEC 2019 Trust dated October 1, 2019.
F3 Securities held in the name of the RTC 2019 Trust dated October 1, 2019.
F4 25% of the shares subject to the stock option shall vest on the first anniversary of the grant date, and the remaining shares shall vest in 36 equal monthly installments thereafter.